Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

Shenton Research

Shenton Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>The HS TECH rebalance will be effective on 7 Sep 2026 before market open, with one ADD and one DELETE.</li>
<li>Iluvatar Corex's bridge return was -5.0% and Tongcheng Travel's was -10.0%, both following declines in the pre-announcement window.</li>
<li>Both names fall into negative-bridge historical groups. Those groups mostly extended lower into the first implementation week.</li>
</ul>


The HS TECH rebalance will be effective on 7 Sep 2026 before market open, with one ADD and one DELETE.
Iluvatar Corex's bridge return was -5.0% and Tongcheng Travel's was -10.0%, both following declines in the pre-announcement window.
Both names fall into negative-bridge historical groups. Those groups mostly extended lower into the first implementation week.


HS TECH Sep 2026 Index Rebalance: Pre-Implementation Update

Iluvatar CoreX

HS TECH Sep 2026 Index Rebalance: Pre-Implementation Update